Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 9, 2007, Pages 10-15

  Joffe, Hadine ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; CONTRACEPTIVE AGENT; DOPAMINE 2 RECEPTOR; ESTROGEN; LAMOTRIGINE; LITHIUM CARBONATE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ACNE; AMENORRHEA; BIPOLAR DISORDER; BREAST CANCER; COMORBIDITY; DEPRESSION; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; EPILEPSY; FEMALE FERTILITY; FEMALE GENITAL SYSTEM; FEMALE INFERTILITY; GALACTORRHEA; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHYROIDISM; LACTATION; MENARCHE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENDOMETRIUM; FEMALE; HYPERPLASIA; MENSTRUATION DISORDER; PATHOLOGY;

BIPOLAR DISORDER; ENDOMETRIUM; FEMALE; HUMANS; HYPERPLASIA; INFERTILITY, FEMALE; MENSTRUATION DISTURBANCES; OSTEOPOROSIS; PREMENOPAUSE; PSYCHOTROPIC DRUGS;

EID: 35348959026     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Leibenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry 1996;153:163-173
2. Zibin T, Nolet C, O'Croinin F. Bipolar women [letter]. Am J Psychiatry 1997;154:441
3. Wood C, Larsen L, Williams R. Menstrual characteristics of 2,343 women attending the Shepherd Foundation. Aust N Z J Obstet Gynaecol 1979;19:107-110
4. Hall JE. Amenorrhea. In: Carlson KJ, Einstat SA, Frigeletto FD Jr, et al. Primary Care of Women. 2nd ed. St. Louis, Mo: CV Mosby; 2002:328-335
5. Joffe H, Kim DR, Foris JM, et al. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder man by women with unipolar depression and healthy controls. J Clin Psychiatry 2006;67:297-304
6. Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000;61:173-178
7. Amsterdam JD, Winokur A, Lucki I, et al. A neuroendocrine test battery in bipolar patients and healthy subjects. Arch Gen Psychiatry 1983;40:515-521
8. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59:1078-1086
9. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388
10. Betts T, Yarrow H, Dutton N, et al. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003;12:323-329
11. Lane DE. Polycystic ovary syndrome and its differential diagnosis. Obstet Gynecol Surv 2006;61:125-135
12. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786-789
13. Sheehan MT. Polycystic ovarian syndrome: diagnosis and management. Clin Med Res 2004;2:13-27
14. Aherne SA. Polycystic ovary syndrome. Nurs Stand 2004;18:40-44
15. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, ed. Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome. Boston, Mass: Blackwell Scientific Publications; 1992:377-384
16. Polson DW, Adams J, Wadsworth J, et al. Polycystic ovaries: a common finding in normal women. Lancet 1988;1:870-872
17. Joffe H, Taylor AE, Hall JE. Polycystic ovarian syndrome: relationship to epilepsy and antiepileptic drug therapy. J Clin Endocrinol Metab 2001;86:2946-2949
18. Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001;86:2950-2956
19. Herzog AG, Siebel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346
20. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003;53:1028-1042
21. McIntyre RS, Mancini DA, McCann S, et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28-35
22. O'Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-330
23. Joffe H, Hall JE, Cohen LS, et al. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 2003;11:99-108
24. Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005;7:246-259
25. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004;145:799-808
26. Morrell MJ, Isojarvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54:189-199
27. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann Neurol 1996;39:579-584
28. Joffe H, Cohen LS, Suppes T, et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006;60:1378-1381
29. Haddad PM, Hellewell JSE, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports [letter]. J Psychopharmacol 2001;15:293-295
30. Misra M, Papakostas GI, Klibansi A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607-1618
31. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 2000;61(suppl 3):10-15
32. Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002;59:1145-1154
33. Popovic V, Damjanovic S, Micic D, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998;49:441-445
34. Mukherjee A, Prasas TK, Rao NM, et al. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells. J Biol Chem 2005;280:15619-15627
35. Harvey PW. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol 2005;25:179-183
36. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-2314
37. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571
38. Sidhu J, Job S, Singh S, et al. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006;61:191-199
39. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine in serum concentrations. Epilepsia 2005;46:1414-1417